AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3262334 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 48
Study 3262334 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 48
Study 29658856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (pemetrexed and a platinum-based drug)
Number of subjects: 616
Study 29658856 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (pemetrexed and a platinum-based drug)
Number of subjects: 616
Study 25643246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural (EPI) with well-functioning catheters
Number of subjects: 55
Study 25643246 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with intravenous narcotics
Number of subjects: 55
Study 25643246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural (EPI) with failed placements
Number of subjects: 55
Study 25597506 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management (TTM) at 33 °C for 24h
Number of subjects: 950
Study 25597506 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management (TTM) at 36 °C for 24h
Number of subjects: 950
Study 25597506 — intervention group
Group type: COMPARATOR
Intervention: Age groups comparison
Number of subjects: 950
Study 22998533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g/day for 8 weeks)
Number of subjects: 30
Study 22998533 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet without flaxseed)
Number of subjects: 30
Study 21647656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 14
Study 21647656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18379534 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PD fluid (1.36%)
Number of subjects: 10
Study 18379534 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PD fluid (3.86%)
Number of subjects: 10
Study 18379534 — intervention group
Group type: COMPARATOR
Intervention: Biocompatible PD fluid (1.36%)
Number of subjects: 10
Study 18379534 — intervention group
Group type: COMPARATOR
Intervention: Biocompatible PD fluid (3.86%)
Number of subjects: 10
Study 18379534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% glucose-containing fluid
Number of subjects: 10
Study 18379534 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose-containing fluid
Number of subjects: 10
Study 16670153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training combined with dietary intervention (EX + DIET)
Number of subjects: 0
Study 16670153 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention without endurance exercise training (DIET)
Number of subjects: 0
Study 12784341 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoCyt
Number of subjects: 61
Study 12784341 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 61
Study 11517848 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive nursing intervention over 16 weeks (9 contacts: 5 in person, 4 by telephone)
Number of subjects: 125
Study 9113256 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg orally
Number of subjects: 16
Study 9113256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1396829 — intervention group
Group type: EXPERIMENTAL
Intervention: 51Cr EDTA elimination
Number of subjects: 30
Study 1396829 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 30
Study 1396829 — intervention group
Group type: COMPARATOR
Intervention: 51Cr EDTA elimination with captopril
Number of subjects: 30
Study 1396829 — intervention group
Group type: COMPARATOR
Intervention: Inulin clearance with captopril
Number of subjects: 30
Study 1396829 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-myocardial infarction group
Number of subjects: 30
Study 4061896 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (2.5%) administered at doses of 2, 3, 4, 5, 6, 7, or 8 mg/kg
Number of subjects: 0
Study 31204610 — intervention group
Group type: EXPERIMENTAL
Intervention: Active peer modeling intervention, including exercise prescription and information
Number of subjects: 50
Study 31204610 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (ACG) receiving general health information
Number of subjects: 50
Study 30721637 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day high-fat overfeeding diet
Number of subjects: 40
Study 30721637 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study 30721637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding diet
Number of subjects: 40
Study 30721637 — intervention group
Group type: COMPARATOR
Intervention: Baseline TCF7L2 expression in mature adipose tissue
Number of subjects: 40
Study 30721637 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipogenesis in isolated preadipocytes
Number of subjects: 40
Study 29234038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfate (STS) injection (80 mg, once daily for 14 consecutive days)
Number of subjects: 70
Study 29234038 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 70
Study 26334924 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Accelerated Maximum Likelihood (RAxML)
Number of subjects: 0
Study 23625305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornus mas L. supplementation (50 g twice a day)
Number of subjects: 40
Study 23625305 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 40
Study 21367399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar disk prosthesis surgery with metal on metal lumbar disk prosthesis and postoperative rehabilitation program
Number of subjects: 20
Study 19212897 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy for a minimum of 80 hours during the first year
Number of subjects: 75
Study 19212897 — intervention group
Group type: COMPARATOR
Intervention: Self-initiated exercise (no specific therapy recommended)
Number of subjects: 75
Study 17189955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 43
Study 17189955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12499180 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV with NFV, IDV, SQV, or placebo
Number of subjects: 139
Study 12499180 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 139
Study 12499180 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence scores
Number of subjects: 139
Study 12499180 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV in NNRTI-naive patients
Number of subjects: 139
Study 12499180 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV in NNRTI-experienced patients
Number of subjects: 139
Study 10582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward-tilting (DT) keyboard tray
Number of subjects: 38
Study 10582503 — intervention group
Group type: COMPARATOR
Intervention: Conventional keyboard on a desk
Number of subjects: 38
Study 8559383 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 8559383 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 1925456 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging (2 hours/week for 4 months)
Number of subjects: 94
Study 1925456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no jogging)
Number of subjects: 94
Study 7081139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guerin (BCG) adjuvant immunotherapy plus conventional therapy
Number of subjects: 33
Study 7081139 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 33
Study 6365474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprolene ointment 0.05 percent (betamethasone dipropionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Number of subjects: 81
Study 6365474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermovate ointment 0.05 percent (clobetasone propionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Number of subjects: 81
Study 31296936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 µg per day)
Number of subjects: 366
Study 31296936 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anaemia (IDA)
Number of subjects: 366
Study 28381133 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 76
Study 28381133 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 76
Study 26686960 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 1193
Study 26686960 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day)
Number of subjects: 1193
Study 24498858 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 394
Study 24498858 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 394
Study 22541245 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (320/9 μg twice-daily)
Number of subjects: 742
Study 22541245 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI (320 μg twice-daily)
Number of subjects: 742
Study 19548011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B Professional Care 8500 (PC 8500)
Number of subjects: 66
Study 19548011 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B CrossAction Vitalizer (CAV)
Number of subjects: 66
Study 18689569 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched restructured meat products
Number of subjects: 25
Study 15870046 — intervention group
Group type: EXPERIMENTAL
Intervention: Embol‐X intraaortic filter
Number of subjects: 2297
Study 12932245 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1-34)
Number of subjects: 15
Study 11195901 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical sacral nerve stimulation (SNS)
Number of subjects: 30
Study 8981554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mg)
Number of subjects: 10
Study 8981554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1524321 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oscillation therapy on the Kinetic Treatment Table
Number of subjects: 30
Study 1524321 — intervention group
Group type: COMPARATOR
Intervention: No continuous oscillation therapy (Control)
Number of subjects: 30
Study 6360704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.6 mg, pressurized aerosol)
Number of subjects: 18
Study 6360704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (1.0 mg, pressurized aerosol)
Number of subjects: 18
Study 6360704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.6 mg, dry powder)
Number of subjects: 18
Study 6360704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (1.0 mg, dry powder)
Number of subjects: 18
Study 6360704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31125468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity small-sided real football games (SRF)
Number of subjects: 81
Study 31125468 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity small-sided walking football games (SWF)
Number of subjects: 81
Study 31125468 — intervention group
Group type: COMPARATOR
Intervention: Resting (RF)
Number of subjects: 81
Study 29907864 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary metabolome analysis post TURBT
Number of subjects: 0
Study 29907864 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profiling
Number of subjects: 0
Study 27439509 — intervention group
Group type: EXPERIMENTAL
Intervention: ARDSnet + OLC (Open Lung Concept)
Number of subjects: 15
Study 27439509 — intervention group
Group type: COMPARATOR
Intervention: ARDSnet-24h
Number of subjects: 15
Study 27439509 — intervention group
Group type: COMPARATOR
Intervention: ARDSnet-48h
Number of subjects: 15
Study 24988955 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-2
Number of subjects: 40
Study 22075112 — intervention group
Group type: EXPERIMENTAL
Intervention: Wording approach 1: 'we recommend', 'we suggest'
Number of subjects: 341
Study 22075112 — intervention group
Group type: EXPERIMENTAL
Intervention: Wording approach 2: 'clinicians should', 'clinicians might'
Number of subjects: 341
Study 22075112 — intervention group
Group type: EXPERIMENTAL
Intervention: Wording approach 3: 'we recommend', 'we conditionally recommend'
Number of subjects: 341
Study 22075112 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong recommendations
Number of subjects: 341
Study 20450503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cautery with 0.9% normal saline irrigation
Number of subjects: 0
Study 20450503 — intervention group
Group type: COMPARATOR
Intervention: Monopolar cautery with 1.5% glycine irrigation
Number of subjects: 0
Study 20450503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bipolar and Monopolar)
Number of subjects: 0
Study 17997261 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professional goal setting (Group B)
Number of subjects: 0
Study 17997261 — intervention group
Group type: COMPARATOR
Intervention: Patient goal setting (Group A)
Number of subjects: 0
Study 16156463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Bearing (MB) design
Number of subjects: 42
Study 16156463 — intervention group
Group type: COMPARATOR
Intervention: Posterior Stabilized (PS) design
Number of subjects: 42
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) categories of 120-139 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) categories of 140-159 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) categories of 159 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ranges of 70-79 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ranges of 80-89 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ranges of 89 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) ranges from 54-67 mmHg
Number of subjects: 2939
Study 12195113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) ranges from 67 mmHg
Number of subjects: 2939
Study 10618931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 MAC of sevoflurane
Number of subjects: 8
Study 10618931 — intervention group
Group type: COMPARATOR
Intervention: Control (without sevoflurane)
Number of subjects: 8
Study 8557010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg kg‐1 rocuronium (2 x ED95)
Number of subjects: 30
Study 8557010 — intervention group
Group type: COMPARATOR
Intervention: 0.06 mg kg‐1 priming dose followed by 0.24 mg kg‐1 rocuronium
Number of subjects: 30
Study 1683148 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 53
Study 1683148 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor treatment
Number of subjects: 53
Study 1683148 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 53
Study 7019803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 47
Study 7019803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 47
Study 7019803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31970939 — intervention group
Group type: COMPARATOR
Intervention: TAC-302 (100 to 1200 mg single dose)
Number of subjects: 96
Study 31970939 — intervention group
Group type: COMPARATOR
Intervention: TAC-302 (400 mg single dose)
Number of subjects: 96
Study 31970939 — intervention group
Group type: COMPARATOR
Intervention: TAC-302 (100, 200, or 400 mg multiple doses for 5 days, twice daily)
Number of subjects: 96
Study 31970939 — intervention group
Group type: COMPARATOR
Intervention: TAC-302
Number of subjects: 96
Study 30838446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (Group L40)
Number of subjects: 0
Study 30838446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg (Group L20)
Number of subjects: 0
Study 30838446 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 0
Study 28817744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole (dosage not specified) and topical voriconazole, 1%
Number of subjects: 240
Study 28817744 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5% (added after 39 participants enrolled)
Number of subjects: 240
Study 28817744 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean of the infiltrate (increase by 1 mm)
Number of subjects: 240
Study 25921978 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive coping (measured using the Utrecht Proactive Coping Competence scale - UPCC)
Number of subjects: 112
Study 25921978 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (measured using the General Self‐Efficacy Scale - GSES)
Number of subjects: 112
Study 22836860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous somatostatin
Number of subjects: 67
Study 22836860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no somatostatin)
Number of subjects: 67
Study 21071588 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) 0.5 l/day, containing ∼6.2 mmol of NO(3)(‐)
Number of subjects: 9
Study 21071588 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 9
Study 21071588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) 0.5 l/day, containing ∼0.003 mmol of NO(3)(‐)
Number of subjects: 9
Study 19786904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed (Cis/Pem)
Number of subjects: 0
Study 19786904 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel/bevacizumab (Carb/Pac/Bev)
Number of subjects: 0
Study 16421114 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of periventricular white matter hyperintensities (PVWMH) at baseline
Number of subjects: 554
Study 16421114 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression in volume of periventricular white matter hyperintensities (PVWMH)
Number of subjects: 554
Study 16421114 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence or progression of deep white matter hyperintensities (DWMH)
Number of subjects: 554
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (R)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry (R)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (C)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry (C)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (T)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry (T)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (U)
Number of subjects: 36
Study 15248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry (U)
Number of subjects: 36
Study 11371408 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive treadmill walking in patients with CHF
Number of subjects: 8
Study 11371408 — intervention group
Group type: COMPARATOR
Intervention: Exhaustive treadmill walking in healthy subjects
Number of subjects: 8
Study 9062599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 1 mg/kg
Number of subjects: 60
Study 9062599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 2 mg/kg
Number of subjects: 60
Study 9062599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 2.89 mg/kg
Number of subjects: 60
Study 8376436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine injection into the wound (n = 30)
Number of subjects: 60
Study 8376436 — intervention group
Group type: COMPARATOR
Intervention: None (Control group, n = 30)
Number of subjects: 60
Study 3740650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 2 mg by inhalation
Number of subjects: 8
Study 3740650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 4 mg by inhalation
Number of subjects: 8
Study 3740650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 6 mg by inhalation
Number of subjects: 8
Study 3740650 — intervention group
Group type: COMPARATOR
Intervention: Atropine free base 1.67 mg by intramuscular injection
Number of subjects: 8
Study 30547750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense treatment (four two-weekly standard doses of praziquantel)
Number of subjects: 0
Study 30547750 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (one standard dose of praziquantel)
Number of subjects: 0
Study 26858331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Interferon Alfa-2b (HDI)
Number of subjects: 0
Study 26858331 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 26858331 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion Lymph Node Dissection (CLND)
Number of subjects: 0
Study 26858331 — intervention group
Group type: EXPERIMENTAL
Intervention: CLND + High-Dose Interferon Alfa-2b (HDI)
Number of subjects: 0
Study 26275090 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSTX-Saline
Number of subjects: 84
Study 26275090 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSTX-Bup
Number of subjects: 84
Study 26275090 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSTX-Bup-Epi
Number of subjects: 84
Study 26275090 — intervention group
Group type: COMPARATOR
Intervention: Bup
Number of subjects: 84
Study 26275090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Saline)
Number of subjects: 84